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and feasibility trial. As such, there is not much data to discuss in
this paper. The 20 patients treated did reasonably well, but without
a control group, it is hard to say whether or not this technology
was helpful. But, it is clear that localized drug delivery is the
next big thing in endovascular therapy. Whether this will involve
drug elution or, as in this case, localized drug injection, whether
this will involve treating the intima, media, or adventitia, what
the proper medication or perhaps gene product will be remains
to be seen, but this area is moving forward at immense speed.
My questions are primarily technical:
1. Are there vessel characteristics or issues, such as calciﬁcation,
thrombus, or subintimal wire passage, that limit the use of
this technology?2. Why is there only one needle in the catheter? While it seems to
be able to circumferentially deliver the drug in most cases, is
there a technical reason that the multiple needles could not
be placed helically on the balloon to deliver the drug more
uniformly?
3. Since this does treat a different vessel layer than the drug
eluting balloons, do you see this as complementary or as
competitive technology?
4. This balloon was proposed for use in renal denervation. Is this
still being investigated?
I look forward to seeing your ongoing progress in this work.
Dr Christopher D. Owens. I would like to thank Dr Landry
for his comments on our paper. He is correct that this is only
a safety and feasibility trial and was not designed or powered to
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1024 Owens et al April 2014assess efﬁcacy. This was a ﬁrst in-human study, and we had no prior
knowledge of whether therapeutic agents could be delivered to
peripheral arteries in this manner. In this sense, it was entirely
proof of concept.
These were all pretty challenging cases. There were 50%
occlusions, and the average lesion was about 9 cm. In addition,
most of the lesions involved the popliteal artery, which has been
a problematic area for stents. We were able to deliver dexametha-
sone to the perivascular tissue in all cases. We did not choose to
treat anyone with fresh thrombus. I think that circumferential
calciﬁcation would be a limitation of the technology going
forward, because it is simply a physical barrier for needle or drug
penetration. Circumferential calciﬁcation is problematic forany drug delivery platform. However, we found that if you can
get the needle through the vessel wall, then drugs will diffuse cir-
cumferentially, 360 degrees, around the vessel in most cases
despite partial calciﬁcation.
Regarding whether this is complementary or competitive to
intimal-based drug delivery platforms such as balloons or stents,
I believe this to be complementary. Further, we are targeting
inﬂammation rather than proliferation.
Finally, we have presented our preclinical renal denervation studies
at the Society for Vascular Surgery meeting, whereby we used the bull-
frog catheter to deliver guanethidine to the adventitia of renal arteries
to chemically destroy the sympathetic nerve ﬁbers. Regulatory work is
ongoing so that we can move into early phase human studies.
